Dabrafenib and Trametinib Therapy in a Patient with Performance Status 4 and BRAF V600E-Mutated Poorly Differentiated Thyroid Carcinoma: A Case Report
Case Reports in Oncology · 05.11.2026
DOI: 10.1159/cro/abzag095 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 05.11.2026. Verfasst von Keisuke Fujimoto und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Recent studies have demonstrated the efficacy and safety of BRAF/MEK inhibitors in the treatment of BRAF-mutated thyroid carcinomas. However, these agents have generally been studied in patients with an Eastern Cooperative Oncology Group performance status (PS) of 0–2, and their use in patients with severely impaired PS, particularly PS 4, has not been previously reported. Case Presentation A 66-year-old woman presented with dyspnea and neck discomfort. Chest computed tomography (CT) revealed a calcified nodule in the right thyroid lobe and multiple pulmonary nodules. The patient was then referred to our department for further evaluation and treatment. Right thyroid lobectomy and D2a lymph node dissection were performed, and the patient was diagnosed with a poorly differentiated thyroid carcinoma, pT2N1bM1 (lung), Stage IVB. Genetic testing revealed the presence of a BRAF V600E mutation. Postoperative radioactive iodine (RAI) therapy showed no uptake in the pulmonary metastases. Two months after surgery, she developed a right-sided malignant pleural effusion and was administered lenvatinib. Four months after the initiation of lenvatinib treatment, the patient presented with fatigue and was admitted for hypercalcemia and newly observed reticular opacities on chest CT. Her condition rapidly deteriorated, and CT imaging suggested disease progression with possible anaplastic transformation. Although her PS declined to 4, combination therapy with dabrafenib and trametinib was initiated. Supportive care, including morphine and betamethasone, was subsequently administered for severe dyspnea and poor oral intake. Thereafter, her general condition transiently improved, with recovery of oral intake and mobility and improvement of PS to 2, allowing temporary discharge home.
Conclusion
This case describes transient clinical improvement from PS 4 to PS 2 after initiation of BRAF/MEK inhibitor therapy in conjunction with supportive care in a patient with BRAF V600E-mutated poorly differentiated thyroid carcinoma and clinically suspected anaplastic transformation. Although the relative contributions of targeted therapy and supportive care to the clinical improvement cannot be determined, dabrafenib and trametinib were administered without apparent severe treatment-related adverse events, and the patient was temporarily able to return home despite her severely debilitated condition.
Zitieren
APA
Fujimoto, K., Misaki, M., Tsuji, A., Takehara, E., Takeuchi, T., Miyamoto, N., Sakamoto, S., Fujiwara, S., Inoue, S., Goto, M., Toba, H., & Takizawa, H. (2026). Dabrafenib and Trametinib Therapy in a Patient with Performance Status 4 and BRAF V600E-Mutated Poorly Differentiated Thyroid Carcinoma: A Case Report. Case Reports in Oncology. https://doi.org/10.1159/cro/abzag095
Vancouver
Fujimoto K, Misaki M, Tsuji A, Takehara E, Takeuchi T, Miyamoto N, et al. Dabrafenib and Trametinib Therapy in a Patient with Performance Status 4 and BRAF V600E-Mutated Poorly Differentiated Thyroid Carcinoma: A Case Report. Case Reports in Oncology. 2026. doi:10.1159/cro/abzag095
BibTeX
@article{Fujimoto2026,
author = {Fujimoto, Keisuke and Misaki, Mariko and Tsuji, Ayaka and Takehara, Emi and Takeuchi, Taihei and Miyamoto, Naoki and Sakamoto, Shinichi and Fujiwara, Satoshi and Inoue, Seiya and Goto, Masakazu and Toba, Hiroaki and Takizawa, Hiromitsu},
title = {Dabrafenib and Trametinib Therapy in a Patient with Performance Status 4 and BRAF V600E-Mutated Poorly Differentiated Thyroid Carcinoma: A Case Report},
journal = {Case Reports in Oncology},
year = {2026},
doi = {10.1159/cro/abzag095}
}
EUVIMED